Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder - A Systematic Review and Meta-analysis.

  title={Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder - A Systematic Review and Meta-analysis.},
  author={Brian Chan and Michele Freeman and Karli K. Kondo and Chelsea K. Ayers and Jessica L Montgomery and Robin Paynter and Devan Kansagara},
AIMS Addiction to methamphetamine/amphetamine (MA/A) is a major public health problem. Currently there are no pharmacotherapies for MA/A use disorder that have been approved for use by the US Food and Drug Administration or the European Medicines Agency. We reviewed the effectiveness of pharmacotherapy for MA/A use disorder to assess the quality, publication bias, and overall strength of the evidence. METHODS Systematic review and meta-analysis. We searched multiple data sources (MEDLINE… 

The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review

Overall, existing research suggests people who use methamphetamine/amphetamines may have lower receipt of MouD, retention in MOUD, and opioid abstinence during MOUd.

Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature

This research will enhance awareness of evidence addressing the effects of psychosocial and pharmacologic interventions for MUD/PMU overall and in sub-populations, both in terms of recent CPGs/reviews and primary studies; inspection of the latter will also help establish the feasibility of future syntheses to compare treatments.

Pharmacotherapy treatment of stimulant use disorder

Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral

Treatment of stimulant use disorder: A systematic review of reviews

There was sufficient evidence to support the efficacy of contingency management programs for treatment of stimulant use disorder, but psychostimulants, n-acetylcysteine, opioid agonist therapy, disulfiram and antidepressant pharmacological interventions were found to have insufficient evidence tosupport or discount their use.

Stimulant Prescription Medications Among Persons Receiving Buprenorphine for Opioid Use Disorder With Prior Drug-Related Poisoning-Evidence of Net-Sum Gain.

  • J. Tsui
  • Medicine, Psychology
    JAMA network open
  • 2022
It is suggested that among persons with OUD, prescription stimulants are associated with a modest increase in the risk for overdose and drugpoisoning, but this risk is offset by improved retention in buprenorphine treatment, which affords protection.

The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals

The data support the notion of 5‐HT2C receptors as a therapeutic target for drug and alcohol abuse and reduce self‐reported alcohol and amphetamine‐type substance use and craving in AUD and MUD participants, respectively.

Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review.

A need to better understand the complex neurobiology of methamphetamine use disorder and to develop interventions aimed at novel biological targets is needed and mental health professionals need to be trained in recognizing early cardiovascular and cerebrovascular warning signs to mitigate the mortality associated with methamphetamine use Disorder.



Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis

Quantitative analyses showed no effect of psychostimulants for sustained abstinence or treatment retention, and the need for more rigorous studies in this research area was identified.

Pharmacological approaches to methamphetamine dependence: a focused review.

Despite the lack of success in most studies to date, increasing efforts are being made to develop medications for the treatment of methamphetamine dependence and several promising agents are targets of further research.

Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

The addition of mirtazapine to substance use counseling decreased methamphetamine use among active users and was associated with decreases in sexual risk despite low to moderate medication adherence.

A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence.

Methylphenidate is an effective treatment for reducing intravenous drug use in patients with severe amphetamine dependence and should be considered as a treatment for nausea, vomiting, and diarrhea.

Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial.

Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent.

Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial

Patients in the riluzole arm experienced significantly greater improvement on all the craving, withdrawal, and depression measures regarding mean score changes from baseline to endpoint and no significant difference was detected between the two arms in terms of incidence of adverse events.

A systematic review of cognitive and behavioural therapies for methamphetamine dependence.

INTRODUCTION AND AIMS The use of methamphetamine is widespread and poses significant challenges for treatment providers. Much of the treatment knowledge about this group has been extrapolated from